DCF — AMEND #2 RESEARCH MEDICAL CENTER
Enterprise Value: $-441.9M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-441.9M
Enterprise Value
$-147.4M
PV of Cash Flows
$-294.5M
PV of Terminal Value
$-474.4M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $501.6M | $-23.4M | -5.0% | $-44.6M | $-40.6M |
| Year 2 | $516.6M | $-18.9M | -4.0% | $-40.8M | $-33.7M |
| Year 3 | $532.1M | $-14.2M | -3.0% | $-36.7M | $-27.6M |
| Year 4 | $548.1M | $-11.9M | -2.0% | $-35.1M | $-24.0M |
| Year 5 | $564.5M | $-10.8M | -2.0% | $-34.7M | $-21.6M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-441.9M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$487.0M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.051657227448763034
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5